Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

miR-342-E2F network drives TNBC metastasis

Analysis based on 6 articles · First reported Aug 21, 2026 · Last updated Sep 09, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The discovery could expand the use of Pfizer's palbociclib into triple-negative breast cancer, a market with high unmet need, potentially increasing drug sales and benefiting Pfizer. It also validates the miR-342-E2F pathway as a therapeutic target, which may spur investment in related diagnostics and therapies.

Biotechnology Pharmaceuticals Healthcare

Australian researchers from the University of Adelaide and the Ludwig Cancer Research identified a molecular mechanism regulating metastasis in triple-negative breast cancer (TNBC). They found that low levels of miR-342 and high activity of the E2F pathway are associated with increased metastatic risk. In pre-clinical models, restoring miR-342 reduced cancer spread, and the existing CDK4/6 inhibitor palbociclib (marketed by Pfizer) significantly reduced metastatic tumor growth in models with low miR-342. The findings, published in EMBO Molecular Medicine on August 21, 2026, suggest that measuring miR-342 levels could identify TNBC patients who might benefit from CDK4/6 inhibitors, potentially repurposing an existing therapy. The research is pre-clinical; further validation and clinical trials are needed.

priv
Co-lead research institution; contributes to its prestige and potential research collaborations.
Importance 80.0 Sentiment 70.0
stock
Manufacturer of palbociclib; positive pre-clinical results could expand its approved indications, increasing revenue potential.
Importance 70.0 Sentiment 75.0
per
Co-senior author; his work may lead to further research opportunities and recognition.
Importance 60.0 Sentiment 60.0
per
Co-senior author; his involvement strengthens the study's credibility and may boost his research profile.
Importance 60.0 Sentiment 60.0
cnt
Country where research was conducted; may benefit from healthcare advancements and research prestige.
Importance 40.0 Sentiment 50.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.